Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

's first autologous cellular immunotherapy product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Dendreon also is developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer. The Company is headquartered in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including commercialization of PROVENGE. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to refle
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering
2. Dendreon Announces Pricing of Common Stock Offering
3. Dendreon Appoints Hans Bishop as Chief Operating Officer
4. Dendreon Announces Proposed Public Offering of Common Stock
5. Dendreon Receives FDA Acknowledgement of Complete Response
6. Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
7. Dendreon Completes Submission of Biologics License Application for PROVENGE
8. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
11. Dendreon Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... CHICAGO and RARITAN, N.J. ... the international, multi-center, open-label, two-part, single-arm Phase 2 ... – an investigational, human anti-CD38 monoclonal antibody – ... percent (95% CI, 20.8-38.9), as assessed by an ... multiple myeloma. The ORR was consistent among the ...
(Date:5/29/2015)... -- BerGenBio AS ("BerGenBio" or the "Company"), ... on the latest data on BGB324, the Company,s first-in-class, ... kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in ... with the 2015 American Society of Clinical Oncology (ASCO) ... 29 - June 2, 2015. The abstract ...
(Date:5/29/2015)... London, UK (PRWEB) May 29, 2015 ... Co., Ltd. (Chem-Report ) signed a partnership agreement ... is now authorised to distribute and sell research ... Assistant Manager at Partners Department, commented upon the ... creating reports on key petroleum and chemical markets ...
(Date:5/29/2015)... , May 29, 2015  Caris Life Sciences ... fulfilling the promise of precision medicine, today announced ... demonstrate the clinical utility of Caris Molecular Intelligence ... service, in helping to identify targeted treatment options ... each of the studies, results of which are ...
Breaking Biology Technology:Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6
... a portable, miniature microscope in the hope of reducing the time ... 20 cm long and 1 cm wide at its tip, could ... as a surgical guidance tool; dentists could also use it to ... today, Friday 27 April, in IOP Publishing,s Journal of Micromechanics ...
... is king. However, producing the finely tuned particles of light ... to the work by a team of engineers led by ... of Electrical & Computer Engineering, a novel solution has been ... photons faster and easier. Advanced computing technologies such ...
...  IGY Immune Technology & Life Sciences has acquired ... IgY from chicken egg yolks has long been ... in humans as well as its ability to ... good health.  Until now, a consistent, purified source ...
Cached Biology Technology:Handheld probe shows great promise for oral cancer detection 2Research breakthrough takes supercomputing out of the lab 2IGY Immune Technology & Life Sciences Purchases Manufacturing Facility to Produce Purified Immunoglobulin Y (IgY) 2
(Date:5/6/2015)... , May 6, 2015 LifeBEAM, a developer ... helmet producer, announced today that they will expand their ... world,s first bio-sensing cycling helmet and the first joint ... two new colors in order to give cyclists more ... In addition, LifeBEAM and Lazer announced their plan to ...
(Date:4/21/2015)... -- High crime rate, increasing government ... control systems market in Saudi Arabia ... report by TechSci Research " Saudi Arabia Access Control Systems Market ... market in Saudi Arabia is ... systems market in the Kingdom is growing at a ...
(Date:4/14/2015)... 14, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... 2015 New York Design Awards under the category  ,Product ... City Design Awards are part of a global multi-disciplinary ... ratings from the marketplace, industry and judging panel. Winners ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... at the U.S. Department of Energy's Argonne National Laboratory ... belonging to 19th Century composer Ludwig von Beethoven, consistent ... found in his hair. These results confirm the cause ... bone fragments, confirmed by DNA testing to have come ...
... Today a plethora of dog genome-related materials are published, including ... and a series of primary research articles in the ... the publication by Nature of a high-quality draft ... researchers and the public with informative resources about canine genomics ...
... parasite has protein 'wiring' that differs markedly from the ... could lead to the development of antimalarial drugs that ... the single-cell parasite responsible for an estimated 1 million ... that differs markedly from the cellular circuitry of other ...
Cached Biology News:Argonne researchers confirm lead in Beethoven's illness 2Argonne researchers confirm lead in Beethoven's illness 3Scientists fetch useful information from dog genome publications 2Scientists fetch useful information from dog genome publications 3Scientists fetch useful information from dog genome publications 4Researchers develop new method to help find deadly malaria parasite's Achilles heel 2Researchers develop new method to help find deadly malaria parasite's Achilles heel 3
D.R. Harper (1993) • Includes: essential information on taxonomy, culture and safe handling of viruses, immunology, monoclonal antibodies, antivirals and vaccines....
...
... Purification Kits provide rapid and efficient removal ... products, and salts from PCR products (Figure ... provides two Binding Buffer options for fragments ... be performed in either single column or ...
... Zero Blunt TOPO PCR ... fastest and easiest method ... or equal to95%) cloning ... amplified with proofreading thermostable ...
Biology Products: